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Brose and colleagues [1] used a national data set from Great Britain to demonstrate that, in 
current tobacco cigarette smokers, daily but not non-daily electronic cigarette (e-cig) use 
shows a significant association with increased tobacco smoking cessation attempts and 
reductions in smoking behavior. However, e-cig use was not shown in this study to be 
associated significantly with tobacco smoking cessation. Taken together, this new study [1] 
and the extant literature (e.g. [2, 3]) provide little empirical support for the contention that e-
cig use leads reliably to smoking cessation for the majority of users.
Tobacco cigarette smokers self-administer the stimulant drug nicotine with every puff that 
they inhale, and most of them are dependent on the drug [4]. This dependence makes 
cessation difficult, in part because of an aversive abstinence syndrome that occurs during a 
cessation attempt (e.g. [5]). Nicotine replacement medications act by delivering nicotine to 
the user and thus suppressing at least some aversive abstinence symptoms: the more 
nicotine, the greater the symptom suppression (e.g. [6]). E-cigs are not marketed as 
medications in many countries, but are a class of products that use an electric heater to 
aerosolize a liquid that usually contains some combination of propylene glycol, vegetable 
glycerin, flavorants and nicotine. Despite not being marketed as medications, many smokers 
are attempting to quit tobacco cigarettes by using e-cigs daily; however, there is little 
information regarding the long-term health risks associated with daily e-cig use. Putting 
aside that concern, if daily e-cig use is to lead to smoking cessation for the majority of users, 
then e-cigs will probably need to deliver nicotine in doses necessary to suppress abstinence 
symptoms as effectively as a tobacco cigarette. Unfortunately, there is wide variability in e-
cig nicotine delivery: 10 puffs from an e-cig may, for example [7], or may not [8], result in 
reliable nicotine delivery to the user’s blood. Differences across studies can be explained by 
a combination of factors, including characteristics of the e-cig device and liquid, as well as 
user behavior [9]. Those e-cig device/liquid combinations that are most likely to lead to 
smoking cessation may well be those that approximate the nicotine delivery profile of a 
tobacco cigarette (e.g. [10]).
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Strangely, e-cigs that are far less effective at delivering nicotine continue to be marketed to 
smokers. For instance, 50 puffs from either of two Blu e-cig (Lorillard, Inc., Greensboro, 
NC, USA) models that are currently available on the US market deliver 23–53% less 
nicotine to the user relative to approximately 10 puffs from a conventional tobacco cigarette 
[11], yet Blu e-cig brands are rated as the most popular among US young adults [12]. 
Perhaps relatedly, more than 80% of all US televised e-cig advertisements geared toward 
youth and young adults were for Blu e-cigs [13], and 90% of all US advertising expenditures 
for e-cig brands have been for Blu E e-cigs [14]. The fact that some e-cigs that are 
advertised to youth and young adults actively also deliver very little nicotine is reminiscent 
of so-called ‘starter products’ common in the smokeless tobacco arena [15]. Starter products 
allow nicotine-naive users to self-administer low doses of nicotine without experiencing 
drug-mediated adverse side effects and then, as tolerance develops, these users can 
‘graduate’ to products that deliver increasing doses of the drug (e.g. [15]). Public health 
policy-makers may want to recall this industry strategy when considering regulatory action 
regarding e-cigs.
Further complicating this issue is that at least 466 distinct brands of e-cigs are marketed 
currently [16], some by major tobacco companies. Tobacco companies in particular may be 
interested in smokers who purchase an e-cig as part of a smoking cessation strategy but, as 
Brose et al.’s [1] data suggest, ultimately do not quit smoking, perhaps because the e-cig 
they bought underperforms a tobacco cigarette in terms of nicotine delivery to the user. 
Under this scenario, the tobacco company that sells the under-performing product profits 
from sales of e-cigs and tobacco cigarettes, while the smoker who purchased the under-
performing product in addition to tobacco cigarettes continues to be at risk for tobacco-
caused disease and death.
Much has been written about the potential for e-cigs to provide public health benefit through 
a dramatic reduction in tobacco cigarette smoking (e.g. [17]). This potential benefit may 
require science-based regulatory intervention to ensure that e-cigs deliver nicotine 
effectively to cigarette smokers, while avoiding e-cig-induced nicotine dependence in non-
smokers via the starter product strategy. Also, some e-cig device/liquid combinations on the 
market today may deliver nicotine more effectively than the highly addictive tobacco 
cigarette [18]; there is no clear public health rationale for such products, and regulation can 
help to limit their availability. Relevant foci for regulatory intervention that address drug 
delivery include product characteristics [9] and nicotine flux [19]. Without meaningful, 
science-based regulation, there may be many future opportunities to report, as do Brose et al. 
[1], that e-cigs are not effective tools for helping the majority of smokers to quit using lethal 
tobacco cigarettes.
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